期刊
EXPERT OPINION ON INVESTIGATIONAL DRUGS
卷 18, 期 10, 页码 1559-1564出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543780903173222
关键词
acute myeloid leukemia; clofarabine; leukemia; myelodysplastic syndrome; nucleoside analogues
资金
- NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER
- NCI NIH HHS [P30 CA016672] Funding Source: Medline
Clofarabine is a second-generation purine nucleoside analogue. it works mainly by inhibiting ribonucleotide reductase and incorporating into DNA. Clofarabine has shown efficacy in selected pediatric leukemias. It has also shown significant efficacy alone and in combination with other drugs in treating adult myeloid leukemias and high-risk myelodysplastic syndromes. Further, there is significant promise for clofarabine in the treatment of older patients with acute myeloid leukemia who are unlikely to benefit from standard induction chemotherapy due to unfavorable baseline prognostic factors. An oral formulation of clofarabine is also currently under development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据